Selank / Semax Blend

The Selank / Semax Blend is a two-component neuro-nootropic research blend combining 5 mg of Selank and 5 mg of Semax in a single lyophilized vial (10 mg total). Both compounds come from the same Russian regulator-peptide tradition at the Institute of Molecular Genetics of the Russian Academy of Sciences — the Myasoedov group's Pro-Gly-Pro C-terminal extension strategy applied to two different parent sequences. Selank is derived from tuftsin (the natural IgG-derived immune-modulator tetrapeptide) and delivers anxiolysis; Semax is derived from ACTH(4-10) and delivers cognitive activation. Both are approved medicines in Russia and some CIS countries in their individual forms (see the component pages for the full regulatory picture); neither is FDA- or EMA-authorised. The blend format itself has no regulatory authorisation anywhere.

The mechanistic pairing is coherent. Selank acts primarily as a positive allosteric modulator at a benzodiazepine-independent site on the GABA-A receptor — the same receptor family benzodiazepines engage, but at a different binding site and with a fundamentally different pharmacology (no sedation, no cognitive impairment, no dependence). Semax acts primarily through ACTH(4-10)-derived upregulation of BDNF and NGF gene expression, driving cognitive activation and neuroplasticity. The two act on non-overlapping receptor systems and produce no pharmacological conflict. In the blend, Selank calms and Semax activates — covering both ends of the stress-cognition spectrum simultaneously.

Practical use follows two documented routes from the source PDF. For subcutaneous injection: reconstitute the 10 mg total vial with 2.0 mL of bacteriostatic water to give 2.5 mg/mL of each component. For intranasal: reconstitute with 2.0 mL of sterile saline (rather than bacteriostatic water; the different diluent reflects the sensitivity of nasal mucosa) at the same concentration. In either format the reference dose is 0.1–0.2 mL (0.25–0.5 mg of each component), delivered 1–2 times per day. The reference cycling framework is 4–8 weeks on with a 2–4 week washout.

Blend-specific human trial evidence does not exist. Component-level evidence (Russian clinical registrations for both compounds; see Selank and Semax pages) supports the individual peptides but has not been combined into a randomised placebo-controlled trial of the specific two-way combination. Consumer discussions that treat combined component evidence as if it were combination trial evidence are conflating two different things. That framing distinction should be preserved.

The Selank / Semax Blend is a two-component neuro-nootropic research blend combining 5 mg of Selank and 5 mg of Semax in a single lyophilized vial (10 mg total). Both compounds come from the same Russian regulator-peptide tradition at the Institute of Molecular Genetics of the Russian Academy of Sciences — the Myasoedov group's Pro-Gly-Pro C-terminal extension strategy applied to two different parent sequences. Selank is derived from tuftsin (the natural IgG-derived immune-modulator tetrapeptide) and delivers anxiolysis; Semax is derived from ACTH(4-10) and delivers cognitive activation. Both are approved medicines in Russia and some CIS countries in their individual forms (see the component pages for the full regulatory picture); neither is FDA- or EMA-authorised. The blend format itself has no regulatory authorisation anywhere.

The mechanistic pairing is coherent. Selank acts primarily as a positive allosteric modulator at a benzodiazepine-independent site on the GABA-A receptor — the same receptor family benzodiazepines engage, but at a different binding site and with a fundamentally different pharmacology (no sedation, no cognitive impairment, no dependence). Semax acts primarily through ACTH(4-10)-derived upregulation of BDNF and NGF gene expression, driving cognitive activation and neuroplasticity. The two act on non-overlapping receptor systems and produce no pharmacological conflict. In the blend, Selank calms and Semax activates — covering both ends of the stress-cognition spectrum simultaneously.

Practical use follows two documented routes from the source PDF. For subcutaneous injection: reconstitute the 10 mg total vial with 2.0 mL of bacteriostatic water to give 2.5 mg/mL of each component. For intranasal: reconstitute with 2.0 mL of sterile saline (rather than bacteriostatic water; the different diluent reflects the sensitivity of nasal mucosa) at the same concentration. In either format the reference dose is 0.1–0.2 mL (0.25–0.5 mg of each component), delivered 1–2 times per day. The reference cycling framework is 4–8 weeks on with a 2–4 week washout.

Blend-specific human trial evidence does not exist. Component-level evidence (Russian clinical registrations for both compounds; see Selank and Semax pages) supports the individual peptides but has not been combined into a randomised placebo-controlled trial of the specific two-way combination. Consumer discussions that treat combined component evidence as if it were combination trial evidence are conflating two different things. That framing distinction should be preserved.

No blend-specific research literature exists. The relevant evidence lives at the component level: Selank (Myasoedov 2011 developer review; Kozlovskaya 2001 clinical) and Semax (Gusev / Skvortsova stroke work; Myasoedov review). See the individual compound pages.

The blend format has no regulatory authorisation anywhere. Individual components have Russian regulatory registrations (see the Selank and Semax pages).

No blend-specific human trial has been published.